Clinical trials: Upper Limbs
Soft Tissue Sarcoma
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
This is a Phase 2, single-arm, Japanese multicenter trial to evaluate the safety, tolerability, and efficacy of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue…
- Trial name
- NCT02255110
- Testing
- TH-302, Doxorubicin
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Triple Negative Breast Cancer
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
This is a phase II, single-centered, open-label, single-armed study in patients with early triple-negative breast cancer that will evaluate the pathological complete response (pCR) rate of a non-anthracycline-based…
- Trial name
- NCT06407310
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Volunteers
- 25 people
- Sponsor
- Tel Aviv Medical Center
Breast Cancer
Arm Function and Quality of Life Following Mastectomy.
To measure arm function and quality of life of mastectomy patients.
- Trial name
- NCT00379106
- Testing
- Arm exercises., Arm Exercises
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of New Mexico
Stroke
Impact of Training on Gait and Strength in Stroke Survivors
Background: A discrepancy between strength gain and gait changes following various training programs aimed at improving gait function after stroke has been noted.
- Trial name
- NCT01818349
- Testing
- isokinetic lower-limb training, isokinetic upper-limb training
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Université de Montréal
Distal Radius Fracture, Loss of Anatomical Alignment After Fracture Reduction
Prospective Evaluation of Cast Bivalving for Pediatric Distal Radius Fractures
Pediatric patients with distal radius fractures are most commonly treated non-operatively with fracture reduction and cast immobilization.
- Trial name
- NCT05716438
- Testing
- Forearm anteroposterior and lateral plain radiograph
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Brooke Army Medical Center
Acute Myeloid Leukemia in Children
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
- Trial name
- CHIP-AML22/Q (NCT06262438)
- Testing
- Quizartinib, Etoposide, Dexrazoxane
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Hepatocellular Carcinoma Non-resectable
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who progressed after prior systemic therapy (targeted ± immunotherapy) are enrolled. Primary endpoint: objective response rate (ORR).
- Trial name
- NCT07192848
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Song Peng
Severe Aplastic Anemia, Aplastic Anaemia
A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.
- Conditions
- Severe Aplastic Anemia, Aplastic Anaemia, Hematopoietic Cell Transplant
- Trial name
- NCT07586735
- Testing
- BFCA conditiong regimen
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University People's Hospital
Cancer, Advanced Solid Malignancies
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
The primary purpose of this study is to explore the safety and tolerability of MEDI-573 in Japanese subjects with advanced solid tumours refractory to standard therapy or for which no standard therapy exists.
- Trial name
- NCT01340040
- Testing
- MEDI-573
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Physical Therapy
Comparison of the Effects of Turkish Get Up Exercise and Stabilization Exercises on Muscular Activation, Core Stability and Upper Extremity Performance in Healthy Individuals
Turkish Get Up (TGU) exercise, which is one of the kettlebell exercises, is a multi-step, progression-based, functional and whole-body exercise method that includes a combination of movements such as lunge, bridge building and…
- Trial name
- NCT05261789
- Testing
- Turkish Get Up exercise, Core Stability exercise, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Ankara Yildirim Beyazıt University
Diffuse Large B-Cell Lymphoma
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
This is a prospective, multicenter, single-arm clinical study designed to evaluate the efficacy and safety of Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for…
- Trial name
- NCT07001540
- Testing
- Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Cerebrospinal Fluid Leak
Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
The objective of the study is to clinically assess the safety and effectiveness of LIQOSEAL® as a means of reducing intra- as well as post-operative CSF leakage in patients undergoing elective cranial intradural surgery with a…
- Trial name
- ENCASE-II (NCT04086550)
- Testing
- LIQOSEAL, DuraSeal, Adherus
- Where
- 17 sites in United States, Austria and 5 more
- Volunteers
- 228 people
- Sponsor
- Polyganics BV
Actinic Keratoses
Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis
Therapeutic Equivalence of Diclofenac Sodium Gel 3% and Solaraze ®, in the treatment of Actinic Keratosis
- Trial name
- NCT03826550
- Testing
- Diclofenac Sodium Gel, Solaraze 3% Topical Gel
- Where
- 24 sites in United States
- Volunteers
- 655 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Pancreatic Cancer
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
The aim of this study is to explore the efficacy and safety of a new combination regimen of GnP regimen, SBRT and the anti-PD-1/VEGF bis-antibody, Ivonescimab, in patients with recurrent metastatic advanced pancreatic cancer.
- Trial name
- NCT06991491
- Testing
- GnP in combination with Ivonescimab and SBRT
- Volunteers
- 29 people
- Sponsor
- West China Hospital
Anti-Hepatitis A Antibody Levels in Heathy Subjects
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
This was a single center, open-label, single-arm study in which approximately 28 Hepatitis A virus (HAV)-seronegative healthy subjects were enrolled.
- Trial name
- GamaSTAN (NCT03351933)
- Testing
- Immune Globulin (Human)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Grifols Therapeutics LLC
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD).
- Trial name
- NCT07838155
- Testing
- Donanemab
- Where
- 12 sites in India
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
This is an single arm, open-label, phase II trial to evaluate safety and efficacy of using the combination of Camrelizumab with apatinib as second-line therapy for advanced PDAC.
- Trial name
- NCT04415385
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Lymphoma, Non-Hodgkin
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented.
- Trial name
- NCT01843868
- Testing
- Standard anti-emetics in conjunction with R-CHOP
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Refractory Metastatic Colorectal Cancer, pMMR
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
This is a single-arm,open-label, prospective, single-center Study of QL1101 and JS001 in patients with pMMR/MSS refractory metastatic colorectal cancer.
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- BEVTOR (NCT04527068)
- Testing
- Bevacizumab, Tripleitriumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine